Ginsenoside Rg1 ameliorates oxidative stress and myocardial apoptosis in streptozotocin-induced diabetic rats

Journal of Zhejiang University: Science B

Volumn 16, Issue 5, 2015, Pages 344-354

  Yu, Hai tao ^a   Zhen, Juan ^a   Pang, Bo ^b   Gu, Jin ning ^c   Wu, Sui sheng ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b Department of Cardiovascular Medicine PLA No 208 Hospital   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Caspase 3 (CASP3); Diabetic cardiomyopathy; Ginsenoside Rg1; Oxidative stress

Indexed keywords

CASPASE 3; CATALASE; CREATINE KINASE MB; GINSENOSIDE RG 1; GLUCOSE; GLUTATHIONE PEROXIDASE; LIPID; PROTEIN BCL XL; SUPEROXIDE DISMUTASE; TROPONIN I; BCL2L1 PROTEIN, RAT; CASP3 PROTEIN, RAT; CENTRAL NERVOUS SYSTEM AGENTS; GINSENOSIDE; GLUCOSE BLOOD LEVEL; MALONALDEHYDE; PROTEIN BCL X; STREPTOZOCIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DOSE RESPONSE; HEART MUSCLE INJURY; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSMISSION ELECTRON MICROSCOPY; TUNEL ASSAY; ANALYSIS; ANIMAL; CARDIAC MUSCLE; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HEART; METABOLISM; PATHOLOGY; ULTRASTRUCTURE; WISTAR RAT;

RATTUS;

ANIMALS; APOPTOSIS; BCL-X PROTEIN; BLOOD GLUCOSE; CASPASE 3; CENTRAL NERVOUS SYSTEM AGENTS; DIABETES MELLITUS, EXPERIMENTAL; GINSENOSIDES; HEART; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MALONDIALDEHYDE; MICROSCOPY, ELECTRON, TRANSMISSION; MYOCARDIUM; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN;

EID: 84929145032     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1400204     Document Type: Article

References (44)

1. Aneja, A., Tang, W., Bansilal, S., et al., 2008. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am. J. Med., 121(9):748–757. [doi:10.1016/j.amjmed.2008.03.046]
2. Asrih, M., Steffens, S., 2013. Emerging role of epigenetics and miRNA in diabetic cardiomyopathy. Cardiovasc. Pathol., 22(2):117–125. [doi:10.1016/j.carpath.2012.07.004]
3. Bäcklund, T., Palojoki, E., Saraste, A., et al., 2004. Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes. Diabetologia, 47(2):325–330. [doi:10.1007/s00125-003-1311-5]
4. Beulens, J.W., Grobbee, D.E., Nealb, B., 2010. The global burden of diabetes and its complications: an emerging pandemic. Eur. J. Cardiovasc. Prev. Rehabil., 17(Suppl. 1):S3–S8. [doi:10.1097/01.hjr.0000368191.86614.5a]
5. Boyer, J.K., Thanigaraj, S., Schechtman, K.B., et al., 2004. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am. J. Cardiol., 93(7):870–875. [doi:10.1016/j.amjcard.2003.12.026]
6. Brownlee, M., 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865):813–820. [doi:10.1038/414813a]
7. Cai, L., Wang, Y., Zhou, G., et al., 2006. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J. Am. Coll. Cardiol., 48(8):1688–1697. [doi:10.1016/j.jacc.2006.07.022]
8. Carrington, E.M., McKenzie, M.D., Jansen, E., et al., 2009. Islet β-cells deficient in Bcl-xL develop but are abnormally sensitive to apoptotic stimuli. Diabetes, 58(10):2316–2323. [doi:10.2337/db08-1602]
9. Chen, J., Cha-Molstad, H., Szabo, A., et al., 2009. Diabetes induces and calcium channel blockers prevent cardiac expression of proapoptotic thioredoxin-interacting protein. Am. J. Physiol. Endocrinol. Metab., 296(5):E1133–E1139. [doi:10.1152/ajpendo.90944.2008]
10. Chowdhry, M.F., Vohra, H.A., Galiñanes, M., 2007. Diabetes increases apoptosis and necrosis in both ischemic and nonischemic human myocardium: role of caspases and poly-adenosine diphosphate-ribose polymerase. J. Thorac. Cardiovasc. Surg., 134(1):124–131. [doi:10.1016/j.jtcvs.2006.12.059]
11. Deng, J., Wang, Y.W., Chen, W.M., et al., 2010. Role of nitric oxide in ginsenoside Rg1-induced protection against left ventricular hypertrophy produced by abdominal aorta coarctation in rats. Biol. Pharm. Bull., 33(4):631–635. [doi:10.1248/bpb.33.631]
12. Falcão-Pires, I., Leite-Moreira, A.F., 2012. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail. Rev., 17(3):325–344. [doi:10.1007/s10741-011-9257-z]
13. Giacco, F., Brownlee, M., 2010. Oxidative stress and diabetic complications. Circ. Res., 107(9):1058–1070. [doi:10.1161/CIRCRESAHA.110.223545]
14. Halliwell, B., 2007. Biochemistry of oxidative stress. Biochem. Soc. Trans., 35(5):1147–1150. [doi:10.1042/BST0351147]
15. Hamblin, M., Friedman, D.B., Hill, S., et al., 2007. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J. Mol. Cell. Cardiol., 42(4):884–895. [doi:10.1016/j.yjmcc.2006.12.018]
16. Huang, Y., Wu, D., Fan, W., 2014. Protection of ginsenoside Rg1 on chondrocyte from IL-1β-induced mitochondriaactivated apoptosis through PI3K/Akt signaling. Mol. Cell. Biochem., 392(1–2):249–257. [doi:10.1007/s11010-014-2035-1]
17. Kannel, W.B., McGee, D.L., 1979. Diabetes and cardiovascular disease: the Framingham study. JAMA, 241(19):2035–2038. [doi:10.1001/jama.1979.03290450033020]
18. Khullar, M., Al-Shudiefat, A.A.R.S., Ludke, A., et al., 2010. Oxidative stress: a key contributor to diabetic cardiomyopathy. Can. J. Physiol. Pharmacol., 88(3):233–240. [doi:10.1139/Y10-016]
19. Korivi, M., Hou, C.W., Huang, C.Y., et al., 2012. Ginsenoside-Rg1 protects the liver against exhaustive exerciseinduced oxidative stress in rats. Evid. Based Complement. Alternat. Med., 2012:932165. [doi:10.1155/2012/932165]
20. Leung, K.W., Pon, Y.L., Wong, R.N., et al., 2006. Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and β-catenin/T-cell factordependent pathway in human endothelial cells. J. Biol. Chem., 281(47):36280–36288. [doi:10.1074/jbc.M606698200]
21. Li, C.Y., Deng, W., Liao, X.Q., et al., 2013. The effects and mechanism of ginsenoside Rg1 on myocardial remodeling in an animal model of chronic thromboembolic pulmonary hypertension. Eur. J. Med. Res., 18:16. [doi:10.1186/2047-783X-18-16]
22. Li, J.H., Zhang, N., Wang, J.A., 2008. Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J. Endocrinol. Invest., 31(2):103–110. [doi:10.1007/BF03345575]
23. Liu, H.R., Tao, L., Gao, E., et al., 2009. Rosiglitazone inhibits hypercholesterolaemia-induced myeloperoxidase upregulation—a novel mechanism for the cardioprotective effects of PPAR agonists. Cardiovasc. Res., 81(2):344–352. [doi:10.1093/cvr/cvn308]
24. Liu, J.W., Liu, D., Cui, K.Z., et al., 2012. Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy. Biochem. Biophys. Res. Commun., 427(3):441–443. [doi:10.1016/j.bbrc.2012.09.058]
25. Lü, J.M., Yao, Q., Chen, C., 2009. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr. Vasc. Pharmacol., 7(3):293. [doi:10.2174/157016109788340767]
26. Ma, J., Liu, J., Wang, Q., et al., 2013. The beneficial effect of ginsenoside Rg1 on Schwann cells subjected to hydrogen peroxide induced oxidative injury. Int. J. Biol. Sci., 9(6):624–636. [doi:10.7150/ijbs.5885]
27. Matsui, T., Davidoff, A.J., 2007. Assessment of PI-3 kinase and Akt in ischemic heart diseases in diabetes. Methods Mol. Med., 139:329–338. [doi:10.1007/978-1-59745-571-8_22]
28. Morrissy, S., Xu, B., Aguilar, D., et al., 2010. Inhibition of apoptosis by progesterone in cardiomyocytes. Aging Cell, 9(5):799–809. [doi:10.1111/j.1474-9726.2010.00619.x]
29. Ogata, Y., Takahashi, M., 2003. Bcl-xL as an antiapoptotic molecule for cardiomyocytes. Drug News Perspect., 16(7):446–452. [doi:10.1358/dnp.2003.16.7.829356]
30. Park, S.H., Jang, J.H., Chen, C.Y., et al., 2010. A formulated red ginseng extract rescues PC12 cells from PCB-induced oxidative cell death through Nrf2-mediated upregulation of heme oxygenase-1 and glutamate cysteine ligase. Toxicology, 278(1):131–139. [doi:10.1016/j.tox.2010.04.003]
31. Rubler, S., Dlugash, J., Yuceoglu, Y.Z., et al., 1972. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol., 30(6):595–602. [doi:10.1016/0002-9149(72)90595-4]
32. Shi, C., Zheng, D.D., Fang, L., et al., 2012. Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/Akt. Biochim. Biophys. Acta, 1820(4):453–460. [doi:10.1016/j.bbagen.2011.12.005]
33. Singal, P.K., Bello-Klein, A., Farahmand, F., et al., 2001. Oxidative stress and functional deficit in diabetic cardiomyopathy. Adv. Exp. Med. Biol., 498:213–220. [doi:10.1007/978-1-4615-1321-6_27]
34. Thandavarayan, R.A., Watanabe, K., Ma, M., et al., 2009. Dominant-negative p38α mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol., 297(3):H911–H919. [doi:10.1152/ajpheart.00124.2009]
35. Voulgari, C., Papadogiannis, D., Tentolouris, N., 2010. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc. Health Risk Manag., 6:883–903. [doi:10.2147/VHRM.S11681]
36. Wang, Q.Y., Liu, F., Wu, F.J., et al., 2013. Effects of ginsenoside Rg1 on the expressions of p-eRK1/2 and p-JNK in local cerebral ischemia/reperfusion injury rats. Chin. J. Integr. Tradit. West. Med., 33(2):229–234 (in Chinese).
37. Wang, Y., Liu, Y., Zhang, X.Y., et al., 2014. Ginsenoside Rg1 regulates innate immune responses in macrophages through differentially modulating the NF-kB and PI3K/ Akt/mTOR pathways. Int. Immunopharmacol., 23(1):77–84. [doi:10.1016/j.intimp.2014.07.028]
38. Watanabe, I.S., Yamada, E., 1983. The fine structure of lamellated nerve endings found in the rat gingiva. Arch. Histol. Jpn., 46(2):173–182. [doi:10.1679/aohc.46.173]
39. Xia, R., Zhao, B., Wu, Y., et al., 2011. Ginsenoside Rb1 preconditioning enhances eNOS expression and attenuates myocardial ischemia/reperfusion injury in diabetic rats. J. Biomed. Biotechnol., 2011:767930. [doi:10.1155/2011/767930]
40. Xu, J., Wang, G., Wang, Y., et al., 2009. Diabetes-and angiotensin II-induced cardiac endoplasmic reticulum stress and cell death: metallothionein protection. J. Cell. Mol. Med., 13(8A):1499–1512. [doi:10.1111/j.1582-4934.2009.00833.x]
41. Yan, J., Liu, Q., Dou, Y., et al., 2013. Activating glucocorticoid receptor-ERK signaling pathway contributes to ginsenoside Rg1 protection against β-amyloid peptideinduced human endothelial cells apoptosis. J. Ethnopharmacol., 147(2):456–466. [doi:10.1016/j.jep.2013.03.039]
42. Yang, W., Lu, J., Weng, J., et al., 2010. Prevalence of diabetes among men and women in China. N. Engl. J. Med., 362(12):1090–1101. [doi:10.1056/NEJMoa0908292]
43. Yin, H., Liu, Z., Li, F., et al., 2011. Ginsenoside-Rg1 enhances angiogenesis and ameliorates ventricular remodeling in a rat model of myocardial infarction. J. Mol. Med., 89(4):363–375. [doi:10.1007/s00109-011-0723-9]
44. Zhang, Y.J., Zhang, X.L., Li, M.H., et al., 2013. The ginsenoside Rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis. J. Cardiovasc. Pharmacol., 62(1):50–57. [doi:10.1097/FJC.0b013e31828f8d45]